IDEXX shares traded at $557.44 in an October 19, 2026 market snapshot, down 0.52% for the day and 1.76% over three months. The veterinary diagnostics company’s modest share-price decline contrasts with growth in its previously reported 2025 revenue and earnings, although those historical results do not establish the cause of the stock move or its future direction.
Key Takeaways
- The October 19 price snapshot showed a daily decline, not a confirmed closing price.
- Recurring diagnostic testing, consumables and services are central to IDEXX’s business.
- Fiscal 2025 revenue rose 10%, while reported earnings growth also benefited from a litigation-related comparison.
Table of Contents
- IDEXX shares show modest recent weakness
- Recurring testing revenue anchors the business
- Historical earnings growth needs a comparable view
- Conclusion
IDEXX shares show modest recent weakness
The daily and three-month declines describe the stock’s recent performance but do not, by themselves, demonstrate a change in the company’s operations. The available information does not identify a specific corporate announcement behind the October 19 move.
Separating the trading snapshot from the financial reporting period matters here: the supplied annual results cover 2025 and were announced on February 2, 2026, more than eight months before the share-price observation.
| Item | Details |
|---|---|
| Q4 2025 reference laboratory services | Revenue growth of 11% reported and 9% organic. |
| Q4 2025 veterinary software, services and imaging | Revenue growth of 13% reported and organic. |
| Q4 2025 Water segment | Revenue growth of 12% reported and 10% organic. |
Recurring testing revenue anchors the business
IDEXX develops diagnostic equipment, test kits and laboratory services primarily for companion-animal veterinary practices. It also provides veterinary software and serves livestock, poultry, dairy and water-testing markets.
Its revenue sources extend beyond instrument sales to consumables, laboratory testing and software subscriptions. That distinction makes ongoing testing activity and the installed equipment base useful operating measures alongside new instrument placements.
In the fourth quarter of 2025, IDEXX’s global premium instrument installed base expanded 12% year over year. Companion Animal Group diagnostics recurring revenue grew 12% as reported and 10% organically, with U.S. growth of 9% and international reported growth of 17%.
Historical earnings growth needs a comparable view
IDEXX’s fourth-quarter and full-year 2025 results showed annual revenue of $4.304 billion, up 10% both as reported and organically. Diluted earnings per share reached $13.08, increasing 23% as reported and 14% on the company’s comparable basis.
The gap between those earnings growth rates is important. Reported growth included an approximately seven-percentage-point benefit from comparison with the prior year’s discrete litigation expense accrual.
Fourth-quarter revenue was $1.091 billion, up 14% as reported, while diluted earnings per share increased 18% to $3.08. These figures provide historical operating context rather than evidence of IDEXX’s performance through October 2026.
Conclusion
The October share-price weakness and IDEXX’s historical operating growth are separate developments. Subsequent earnings disclosures will provide the next check on recurring testing revenue and profitability; the 2025 figures alone cannot establish the company’s October 2026 operating position.
Read More News
Disclaimer
This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.
